{"id":"https://openalex.org/W2135802989","doi":"https://doi.org/10.1158/1535-7163.mct-12-1182","title":"Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models","display_name":"Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models","alternate_titles":[],"publication_year":2013,"publication_date":"2013-10-01","ids":{"openalex":"https://openalex.org/W2135802989","doi":"https://doi.org/10.1158/1535-7163.mct-12-1182","mag":"2135802989","pmid":"https://pubmed.ncbi.nlm.nih.gov/23873847"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-12-1182","doi":"https://doi.org/10.1158/1535-7163.mct-12-1182","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-12-1182","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2135802989"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006906885","display_name":"Sylvia Herter","orcid":"https://orcid.org/0000-0002-2446-696X","observed_orcids":["https://orcid.org/0000-0002-2446-696X"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sylvia Herter","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007078235","display_name":"Frank Herting","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Frank Herting","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023182732","display_name":"Olaf Mundigl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Olaf Mundigl","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057235269","display_name":"Inja Waldhauer","orcid":"https://orcid.org/0000-0001-8008-8660","observed_orcids":["https://orcid.org/0000-0001-8008-8660"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Inja Waldhauer","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000210708","display_name":"Tina Weinzierl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tina Weinzierl","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047294939","display_name":"Tanja Fauti","orcid":"https://orcid.org/0009-0002-1994-8099","observed_orcids":["https://orcid.org/0009-0002-1994-8099"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tanja Fauti","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025796029","display_name":"Gunter Muth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gunter Muth","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033389276","display_name":"Doris Ziegler-Landesberger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Doris Ziegler-Landesberger","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025120043","display_name":"Erwin van Puijenbroek","orcid":"https://orcid.org/0009-0000-1349-3762","observed_orcids":["https://orcid.org/0009-0000-1349-3762"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Erwin Van Puijenbroek","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sabine Lang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sabine Lang","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000865204","display_name":"Minh Ngoc Duong","orcid":"https://orcid.org/0000-0001-9840-1459","observed_orcids":["https://orcid.org/0000-0001-9840-1459"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Minh Ngoc Duong","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067770954","display_name":"Lina Reslan","orcid":"https://orcid.org/0000-0002-1496-317X","observed_orcids":["https://orcid.org/0000-0002-1496-317X"]},"institutions":[{"id":"https://openalex.org/I100532134","display_name":"Lyon 1 Universit\u00e9","ror":"https://ror.org/029brtt94","country_code":"FR","type":"education","lineage":["https://openalex.org/I100532134","https://openalex.org/I203339264"]},{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lina Reslan","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","iNSERM 590, Claude Bernard Lyobn University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]},{"raw_affiliation_string":"iNSERM 590, Claude Bernard Lyobn University","institution_ids":["https://openalex.org/I100532134","https://openalex.org/I154526488"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112905292","display_name":"Christian A. Gerdes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christian A. Gerdes","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112474280","display_name":"Thomas Friess","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Thomas Friess","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076378151","display_name":"Ute Baer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ute Baer","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054120901","display_name":"Helmut J. BURTSCHER","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Helmut Burtscher","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael Weidner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael Weidner","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006793451","display_name":"Charles Dumontet","orcid":"https://orcid.org/0000-0003-1875-134X","observed_orcids":["https://orcid.org/0000-0003-1875-134X"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Charles Dumontet","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040318787","display_name":"Pablo Uma\u00f1a","orcid":"https://orcid.org/0000-0001-8206-2771","observed_orcids":["https://orcid.org/0000-0001-8206-2771"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pablo Umana","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016538112","display_name":"Gerhard J. Niederfellner","orcid":"https://orcid.org/0000-0001-5487-2929","observed_orcids":["https://orcid.org/0000-0001-5487-2929"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gerhard Niederfellner","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002292400","display_name":"Marina Bacac","orcid":"https://orcid.org/0000-0003-0581-9579","observed_orcids":["https://orcid.org/0000-0003-0581-9579"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marina Bacac","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067162282","display_name":"Christian Klein","orcid":"https://orcid.org/0000-0001-7594-7280","observed_orcids":["https://orcid.org/0000-0001-7594-7280"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]},{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210125048","display_name":"Centre de Recherche en Canc\u00e9rologie de Lyon","ror":"https://ror.org/02mgw3155","country_code":"FR","type":"facility","lineage":["https://openalex.org/I100532134","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I203339264","https://openalex.org/I4210096427","https://openalex.org/I4210105738","https://openalex.org/I4210125048"]}],"countries":["CH","FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christian Klein","raw_affiliation_strings":["Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland; 2Discovery Oncology and 3Large Molecule Research, Roche Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany; and 4Centre de Recherche en Canc\u00e9rologie de Lyon, Institut National de la Sant\u00e9 et de la Recherche Medicale (INSERM) UMR 1052/CNRS 5286, Lyon, France","institution_ids":["https://openalex.org/I118019719","https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I4210125048"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":23.9824,"has_fulltext":false,"cited_by_count":407,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.99626939,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"12","issue":"10","first_page":"2031","last_page":"2042"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.4790000021457672,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.4790000021457672,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.4584999978542328,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.04100000113248825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":0.9779999852180481},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9259999990463257},{"id":"https://openalex.org/keywords/ofatumumab","display_name":"ofatumumab","score":1.0},{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.906000018119812},{"id":"https://openalex.org/keywords/glycoengineering","display_name":"glycoengineering","score":0.8569999933242798},{"id":"https://openalex.org/keywords/complement-dependent-cytotoxicity","display_name":"complement-dependent cytotoxicity","score":0.8119999766349792},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.9850000143051147},{"id":"https://openalex.org/keywords/b-cell-depletion","display_name":"B-cell depletion","score":0.7400000095367432},{"id":"https://openalex.org/keywords/antibody-internalization","display_name":"antibody internalization","score":0.7390000224113464},{"id":"https://openalex.org/keywords/rituximab-resistance","display_name":"rituximab resistance","score":0.7009999752044678},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.765999972820282}],"concepts":[{"id":"https://openalex.org/C2778714382","wikidata":"https://www.wikidata.org/wiki/Q410656","display_name":"Ofatumumab","level":4,"score":0.9835901260375977},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.8670237064361572},{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.843822717666626},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.8044075965881348},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6924524903297424},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.559754490852356},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.5590587258338928},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5520223379135132},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.46005719900131226},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3411635160446167},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3101074993610382},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.12910661101341248},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003602","descriptor_name":"Cytotoxicity, Immunologic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D010587","descriptor_name":"Phagocytosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D010587","descriptor_name":"Phagocytosis","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1158/1535-7163.mct-12-1182","doi":"https://doi.org/10.1158/1535-7163.mct-12-1182","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-12-1182","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:23873847","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23873847","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.967.6544","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.967.6544","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/molcanther/12/10/2031.full.pdf","raw_type":"text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.970.932","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.970.932","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://mct.aacrjournals.org/content/molcanther/early/2013/09/25/1535-7163.MCT-12-1182.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320318807","display_name":"Roche Innovation Center Zurich","ror":null},{"id":"https://openalex.org/F4320320276","display_name":"University of Leicester","ror":"https://ror.org/04h699437"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W1593874097","https://openalex.org/W1721657566","https://openalex.org/W1964486259","https://openalex.org/W1969824500","https://openalex.org/W1988367968","https://openalex.org/W2003089766","https://openalex.org/W2009109361","https://openalex.org/W2010329820","https://openalex.org/W2017416510","https://openalex.org/W2018071905","https://openalex.org/W2021681226","https://openalex.org/W2037044333","https://openalex.org/W2041871285","https://openalex.org/W2055342376","https://openalex.org/W2063792914","https://openalex.org/W2079997015","https://openalex.org/W2083435401","https://openalex.org/W2084042587","https://openalex.org/W2084271278","https://openalex.org/W2091057822","https://openalex.org/W2091435332","https://openalex.org/W2109687784","https://openalex.org/W2122725450","https://openalex.org/W2129358485","https://openalex.org/W2135321054","https://openalex.org/W2137752130","https://openalex.org/W2140606816","https://openalex.org/W2141139539","https://openalex.org/W2141346198","https://openalex.org/W2146682305","https://openalex.org/W2147047596","https://openalex.org/W2147639736","https://openalex.org/W2158803162","https://openalex.org/W2159970259","https://openalex.org/W2161563262","https://openalex.org/W2162335998","https://openalex.org/W2168874755","https://openalex.org/W2554421323"],"related_works":["https://openalex.org/W2560361367","https://openalex.org/W2563548240","https://openalex.org/W1593858110","https://openalex.org/W2131909425","https://openalex.org/W2109687784","https://openalex.org/W1995641274","https://openalex.org/W2277640703","https://openalex.org/W2508786914","https://openalex.org/W2555381248"],"abstract_inverted_index":{"We":[0],"report":[1],"the":[2,26,67,90,171,207,212,222],"first":[3],"preclinical":[4,208,235],"in":[5,8,39,72,89,118,129,142,170],"vitro":[6],"and":[7,24,47,61,76,87,127,131,136,156,174,182,230],"vivo":[9,73],"comparison":[10,68],"of":[11,69,92,97],"GA101":[12,79,121,144,160,192,218],"(obinutuzumab),":[13],"a":[14,162],"novel":[15],"glycoengineered":[16],"type":[17,30,214,225],"II":[18,215],"CD20":[19,32,153,216,227],"monoclonal":[20],"antibody,":[21],"with":[22,139,179,191],"rituximab":[23,86,126,155,181,203,229],"ofatumumab,":[25],"two":[27,141,223],"currently":[28],"approved":[29,224],"I":[31,226],"antibodies.":[33],"The":[34,63],"three":[35],"antibodies":[36,228],"were":[37,74,187],"compared":[38,178],"assays":[40],"measuring":[41],"direct":[42,93],"cell":[43,94,102],"death":[44,95],"(AnnexinV/PI":[45],"staining":[46],"time-lapse":[48],"microscopy),":[49],"complement-dependent":[50],"cytotoxicity":[51,55],"(CDC),":[52],"antibody-dependent":[53,57],"cell-mediated":[54,58],"(ADCC),":[56],"phagocytosis":[59],"(ADCP),":[60],"internalization.":[62],"models":[64],"used":[65],"for":[66,101],"their":[70],"activity":[71,124],"SU-DHL4":[75,172],"RL":[77],"xenografts.":[78],"was":[80,111,137,193],"found":[81],"to":[82,85,113,125,152,196],"be":[83],"superior":[84,123,176],"ofatumumab":[88,128,231],"induction":[91],"(independent":[96],"mechanical":[98],"manipulation":[99],"required":[100],"aggregate":[103],"disruption":[104],"formed":[105],"by":[106,232],"antibody":[107,217],"treatment),":[108],"whereas":[109,200],"it":[110],"10":[112],"1,000":[114],"times":[115],"less":[116],"potent":[117],"mediating":[119],"CDC.":[120],"showed":[122,146],"ADCC":[130],"whole-blood":[132],"B-cell":[133],"depletion":[134],"assays,":[135],"comparable":[138],"these":[140],"ADCP.":[143],"also":[145],"slower":[147],"internalization":[148],"rate":[149],"upon":[150],"binding":[151],"than":[154],"ofatumumab.":[157,183],"In":[158],"vivo,":[159],"induced":[161],"strong":[163],"antitumor":[164],"effect,":[165],"including":[166],"complete":[167],"tumor":[168,198],"remission":[169],"model":[173],"overall":[175,234],"efficacy":[177],"both":[180],"When":[184],"rituximab-pretreated":[185],"animals":[186],"used,":[188],"second-line":[189],"treatment":[190],"still":[194],"able":[195],"control":[197],"progression,":[199],"tumors":[201],"escaped":[202],"treatment.":[204],"Taken":[205],"together,":[206],"data":[209],"show":[210],"that":[211],"glyoengineered":[213],"is":[219],"differentiated":[220],"from":[221],"its":[233,239],"activity,":[236],"further":[237],"supporting":[238],"clinical":[240],"investigation.":[241]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2135802989","counts_by_year":[{"year":2026,"cited_by_count":24},{"year":2025,"cited_by_count":34},{"year":2024,"cited_by_count":24},{"year":2023,"cited_by_count":33},{"year":2022,"cited_by_count":28},{"year":2021,"cited_by_count":29},{"year":2020,"cited_by_count":25},{"year":2019,"cited_by_count":37},{"year":2018,"cited_by_count":32},{"year":2017,"cited_by_count":37},{"year":2016,"cited_by_count":30},{"year":2015,"cited_by_count":44},{"year":2014,"cited_by_count":23},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
